ABSI - Absci Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $12.40 DETAILS

Stock News

Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy

Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Jul 02, 2026 09:01 AM • zacks.com

ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study

Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.

Jun 25, 2026 07:26 AM • zacks.com

ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?

ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Jun 25, 2026 03:20 AM • zacks.com

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program

Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.

Jun 24, 2026 05:09 AM • benzinga.com

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

Jun 24, 2026 02:35 AM • globenewswire.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts

Jun 24, 2026 02:30 AM • globenewswire.com

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr.

Jun 12, 2026 05:00 AM • businesswire.com

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Jun 09, 2026 09:12 PM • seekingalpha.com

Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

Jun 05, 2026 01:22 PM • seekingalpha.com

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:

May 20, 2026 04:00 AM • globenewswire.com

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

May 08, 2026 04:01 AM • seekingalpha.com

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.

May 07, 2026 07:26 PM • zacks.com

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026.

May 07, 2026 12:05 PM • globenewswire.com

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

May 04, 2026 04:11 PM • globenewswire.com

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026.

Apr 23, 2026 12:05 PM • globenewswire.com

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Apr 21, 2026 11:40 AM • seekingalpha.com

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference.

Apr 08, 2026 04:00 AM • globenewswire.com

MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis

MiMedx Group (NASDAQ: MDXG - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk MiMedx Group has a beta

Apr 01, 2026 09:22 PM • defenseworld.net

Absci Q4 Earnings Call Highlights

Absci (NASDAQ: ABSI) provided a fourth-quarter and full-year 2025 business update on Monday, highlighting early progress for lead candidate ABS-201, expansion into a second indication, and continued investment in its AI-enabled drug creation platform. ABS-201 advances in the clinic with early safety and PK observations Founder and CEO Sean McClain said Absci "had a strong fourth

Mar 25, 2026 11:07 PM • defenseworld.net

Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201

Absci Corporation is downgraded to Hold due to a lack of differentiation for ABS-101 and a strategic pivot to ABS-201. ABS-101 failed to outperform 2nd-generation TL1A candidates, leading to halted internal development and a search for external partnerships. Focus shifts to ABS-201 for androgenetic alopecia, but meaningful efficacy data won't arrive until late 2026 or early 2027.

Mar 25, 2026 10:48 AM • seekingalpha.com

Price Targets